Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record.

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol

Open access
Arabi, Yaseen, Balkhy, Hanan, Hajeer, Ali H., Bouchama, Abderrezak, Hayden, Frederick G., Al-Omari, Awad, Al-Hameed, Fahad M., Taha, Yusri, Shindo, Nahoko, Whitehead, John, Merson, Laura, AlJohani, Sameera, Al-Khairy, Khalid, Carson, Gail, Luke, Thomas C., Hensley, Lisa, Al-Dawood, Abdulaziz, Al-Qahtani, Saad, Modjarrad, Kayvon, Sadat, Musharaf, Rohde, Gernot, Leport, Catherine, Fowler, Robert·2015·SpringerPlus

Abstract

As of September 30, 2015, a total of 1589 laboratory-confirmed cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization (WHO). At present there is no effective specific therapy against MERS-CoV. The use of convalescent plasma (CP) has been suggested as a potential therapy based on existing evidence from other viral infections. We aim to study the feasibility of CP therapy as well as its safety and clinical and laboratory effects in critically ill patients with MERS-CoV infection. We will also examine the pharmacokinetics of the MERS-CoV antibody response and viral load over the course of MERS-CoV infection. This study will inform a future randomized controlled trial that will examine the efficacy of CP therapy for MERS-CoV infection. In the CP collection phase, potential donors will be tested by the enzyme linked immunosorbent assay (ELISA) and the indirect fluorescent antibody (IFA) techniques for the presence of anti-MERS-CoV antibodies. Subjects with anti-MERS-CoV IFA titer of ≥1:160 and no clinical or laboratory evidence of MERS-CoV infection will be screened for eligibility for plasma donation according to standard donation criteria. In the CP therapy phase, 20 consecutive critically ill patients admitted to intensive care unit with laboratory-confirmed MERS-CoV infection will be enrolled and each will receive 2 units of CP. Post enrollment, patients will be followed for clinical and laboratory outcomes that include anti-MERS-CoV antibodies and viral load. This protocol was developed collaboratively by King Abdullah International Medical Research Center (KAIMRC), Gulf Cooperation Council (GCC) Infection Control Center Group and the World Health Organization-International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC-WHO) MERS-CoV Working Group. It was approved in June 2014 by the Ministry of the National Guard Health Affairs Institutional Review Board (IRB). A data safety monitoring board (DSMB) was formulated. The study is registered at http://www.clinicaltrials.gov (NCT02190799).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40064-015-1490-9

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 202

Metadata

Authors
Arabi, Y., Balkhy, H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al-Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., Merson, L., AlJohani, S., Al-Khairy, K., Carson, G., Luke, T. C., Hensley, L., Al-Dawood, A., Al-Qahtani, S., Modjarrad, K., Sadat, M., Rohde, G., Leport, C., & Fowler, R.
Venue
SpringerPlus
Published
2015-11-19
Volume
4
Issue
1
Pages
709-709
ISSN
2193-1801 (ISSN-L)
OpenAlex
W2176471040
Cited by
202
References
0
FWCI
6.02
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. https://app.cochat.ai/papers/10.1186/s40064-015-1490-9
The paper
Arabi, Y., Balkhy, H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al-Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., Merson, L., AlJohani, S., Al-Khairy, K., Carson, G., Luke, T. C., Hensley, L., Al-Dawood, A., Al-Qahtani, S., Modjarrad, K., . . . Fowler, R. (2015). Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus. https://doi.org/10.1186/s40064-015-1490-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.